359 related articles for article (PubMed ID: 16896314)
41. Pathological dynamics of activated microglia following medial forebrain bundle transection.
Cho BP; Song DY; Sugama S; Shin DH; Shimizu Y; Kim SS; Kim YS; Joh TH
Glia; 2006 Jan; 53(1):92-102. PubMed ID: 16206155
[TBL] [Abstract][Full Text] [Related]
42. The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system.
Vernier P; Moret F; Callier S; Snapyan M; Wersinger C; Sidhu A
Ann N Y Acad Sci; 2004 Dec; 1035():231-49. PubMed ID: 15681811
[TBL] [Abstract][Full Text] [Related]
43. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
[TBL] [Abstract][Full Text] [Related]
44. Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra.
Yamamoto S; Fukae J; Mori H; Mizuno Y; Hattori N
Neurosci Lett; 2006 Apr; 396(3):187-91. PubMed ID: 16386370
[TBL] [Abstract][Full Text] [Related]
45. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
46. Selective noradrenergic vulnerability in α-synuclein transgenic mice.
Sotiriou E; Vassilatis DK; Vila M; Stefanis L
Neurobiol Aging; 2010 Dec; 31(12):2103-14. PubMed ID: 19152986
[TBL] [Abstract][Full Text] [Related]
47. Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection.
Stephenson D; Ramirez A; Long J; Barrezueta N; Hajos-Korcsok E; Matherne C; Gallagher D; Ryan A; Ochoa R; Menniti F; Yan J
J Neurosci Methods; 2007 Jan; 159(2):291-9. PubMed ID: 16949674
[TBL] [Abstract][Full Text] [Related]
48. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease.
Tatton NA
Exp Neurol; 2000 Nov; 166(1):29-43. PubMed ID: 11031081
[TBL] [Abstract][Full Text] [Related]
49. Matrix metalloproteinase-3 contributes to vulnerability of the nigral dopaminergic neurons.
Kim ST; Kim EM; Choi JH; Son HJ; Ji IJ; Joh TH; Chung SJ; Hwang O
Neurochem Int; 2010 Jan; 56(1):161-7. PubMed ID: 19815046
[TBL] [Abstract][Full Text] [Related]
50. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease.
McRitchie DA; Cartwright HR; Halliday GM
Exp Neurol; 1997 Mar; 144(1):202-13. PubMed ID: 9126172
[TBL] [Abstract][Full Text] [Related]
51. Akt signal transduction dysfunction in Parkinson's disease.
Timmons S; Coakley MF; Moloney AM; O' Neill C
Neurosci Lett; 2009 Dec; 467(1):30-5. PubMed ID: 19800394
[TBL] [Abstract][Full Text] [Related]
52. Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation.
Pal GD; Ouyang B; Serrano G; Shill HA; Goetz C; Stebbins G; Metman LV; Driver-Dunckley E; Mehta SH; Caviness JN; Sabbagh MN; Adler CH; Beach TG;
Mov Disord; 2017 Feb; 32(2):274-277. PubMed ID: 27911008
[TBL] [Abstract][Full Text] [Related]
53. Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.
Jiang H; Song N; Wang J; Ren LY; Xie JX
Neurochem Int; 2007 Jul; 51(1):32-6. PubMed ID: 17490790
[TBL] [Abstract][Full Text] [Related]
54. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.
Ulusoy A; Febbraro F; Jensen PH; Kirik D; Romero-Ramos M
Eur J Neurosci; 2010 Aug; 32(3):409-22. PubMed ID: 20704592
[TBL] [Abstract][Full Text] [Related]
55. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
[TBL] [Abstract][Full Text] [Related]
56. Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of alpha-synuclein.
Drolet RE; Behrouz B; Lookingland KJ; Goudreau JL
J Neurochem; 2006 Feb; 96(4):950-9. PubMed ID: 16412098
[TBL] [Abstract][Full Text] [Related]
57. The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs.
Burns JM; Galvin JE; Roe CM; Morris JC; McKeel DW
Neurology; 2005 Apr; 64(8):1397-403. PubMed ID: 15851730
[TBL] [Abstract][Full Text] [Related]
58. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats.
Zeng BY; Bukhatwa S; Hikima A; Rose S; Jenner P
Ann Neurol; 2006 Aug; 60(2):248-52. PubMed ID: 16862581
[TBL] [Abstract][Full Text] [Related]
59. Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice.
O'Neil JN; Mouton PR; Tizabi Y; Ottinger MA; Lei DL; Ingram DK; Manaye KF
J Chem Neuroanat; 2007 Nov; 34(3-4):102-7. PubMed ID: 17658239
[TBL] [Abstract][Full Text] [Related]
60. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease.
Milber JM; Noorigian JV; Morley JF; Petrovitch H; White L; Ross GW; Duda JE
Neurology; 2012 Dec; 79(24):2307-14. PubMed ID: 23152586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
